David A. Siegel Eloxx Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.24 - $0.58 $44,184 - $106,777	-184,100 Reduced 78.88%	49,300 $13,000
Q1 2022 May 16, 2022	SELL	$0.4 - $0.72 $93,840 - $168,912	-234,600 Reduced 50.13%	233,400 $131,000
Q4 2021 Feb 14, 2022	SELL	$0.62 - $1.61 $147,126 - $382,053	-237,300 Reduced 33.65%	468,000 $331,000
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.0 $586,576 - $961,600	480,800 Added 214.16%	705,300 $1.15 Million
Q2 2021 Aug 16, 2021	BUY	$1.35 - $3.36 $303,075 - $754,320	224,500 New	224,500 $447,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.